PDRN 79
Integrating recombinant PDRN and humanized elastin
Sun Qing – Uniproma ABSTRACT
The anti-ageing category is moving beyond the simple addition of hero ingredients toward a more systems-based understanding of skin decline. Ageing skin is not defined by a single deficit. Instead, it reflects cumulative changes in inflammatory tone, DNA repair demand, extracellular matrix turnover, fibroblast responsiveness, barrier quality and tissue mechanics. From this perspective, regeneration- oriented actives are most useful when they address both the biological signals that coordinate repair and the structural materials that determine how skin behaves under mechanical stress. In our current portfolio, this shift is exemplified
by two recombinant ingredients. One is RJMPDRN® REC, a recombinant PDRN ingredient intended to support repair, soothing and matrix regeneration. The other is recombinant humanized elastin, marketed at first use as Arelastin®, which is designed to biomimic the secondary-structure and sequence features that make elastin central to tissue recoil and resilience. Considered together, these materials frame a new anti-ageing model based on cellular recovery plus structural restoration.
Why conventional materials are reaching their limits PDRN has attracted substantial interest in regenerative medicine and cosmetic dermatology because low-molecular-weight DNA fragments have been associated with tissue repair, reduced inflammation and improved extracellular matrix remodelling through adenosine A2A receptor
www.personalcaremagazine.com
activation and salvage-pathway support.1-3 In practice, however, conventional PDRN is
usually sourced from salmon milt. That origin has historically offered low immunogenicity and acceptable purity, but it also introduces well- known development constraints: dependence on biological extraction, natural-source variability, limited scalability, and potential inconsistency in fragment distribution and impurity profiles. These issues are increasingly important as demand for PDRN expands across premium skin care, post- procedure care and repair-focused formulations. Elastin presents a different challenge. In
healthy skin, elastin-containing elastic fibres are responsible for stretch, recoil and long-term mechanical resilience. With intrinsic ageing and photoageing, this network becomes disorganised, fragmented and functionally depleted, contributing to laxity, deeper wrinkles and reduced recovery after deformation.4,5 Yet elastin has been difficult to utilise directly
as a cosmetic biomaterial. Its biofunction depends not only on amino acid sequence but also on higher-order conformation, assembly behaviour, purity and delivery. Many conventional elastin materials act only as indirect biological cues or film-formers rather than as truly structure-relevant replenishment materials. These limitations have helped make
recombinant technology increasingly attractive. Recombinant systems allow tighter control of sequence, size distribution, purity and manufacturing reproducibility, while also reducing dependence on animal-derived sourcing. For
Advances in skin longevity are shifting anti-ageing development from conventional extract-based actives toward sequence- defined biomaterials that can be designed, manufactured and standardised with greater precision. Two recombinant platforms are especially relevant to this transition: recombinant polydeoxyribonucleotide (PDRN) and recombinant humanized elastin. Although both target skin regeneration, they operate at different biological levels. PDRN primarily supports repair signalling by supplying nucleic-acid fragments associated with salvage-pathway activity and adenosine A2A receptor-mediated tissue recovery, while recombinant humanized elastin addresses the structural deficit of ageing skin by replenishing an elastin-mimetic material designed to restore recoil, firmness and barrier quality. In this article, we review the rationale for combining these two approaches in topical anti-ageing and repair formulations. We discuss the limitations of animal-derived PDRN and conventional elastin materials, the technical advantages of recombinant production, and formulation- relevant performance data including safety, collagen stimulation, anti-inflammatory effects, hydration, wrinkle reduction, firmness improvement and broad formulation stability. Taken together, these technologies illustrate how recombinant biomaterials can support a more controllable, sustainable and mechanistically targeted route to precision skin regeneration
formulators and brand developers, that translates into more robust claims support, more stable supply and a cleaner sustainability story.
Recombinant PDRN: from biological extract to sequence-defined repair support Published literature describes PDRN as a mixture of deoxyribonucleotide polymers capable of supporting tissue regeneration, angiogenesis and extracellular matrix production, with part of its activity linked to adenosine A2A receptor signalling and part to the salvage pathway that
September 2026 PERSONAL CARE MAGAZINE
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92
